This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Gilead Inks Deal With Carna Biosciences for Immuno-Oncology
by Zacks Equity Research
Gilead (GILD) teams up with Carna Biosciences to develop and commercialize small molecule compounds in immuno-oncology.
Arbutus Gets Clearance to Initiate Hepatitis Study, Stock Up
by Zacks Equity Research
Arbutus (ABUS) surges on clearance for a clinical study to evaluate its RNAi agent, AB-729 as a treatment for hepatitis B virus.
AstraZeneca's Triple-Combo COPD Inhaler Gets Japan's Nod
by Zacks Equity Research
AstraZeneca (AZN) gets approval in Japan for PT010, its triple-combo inhaler and Bevespi Aerosphere, a fixed-dose LABA/LAMA inhaler, both to treat COPD.
Gilead (GILD) Teams Up With Nurix for Cancer and Other Drugs
by Zacks Equity Research
Gilead (GILD) collaborates with Nurix Therapeutics to leverage the proprietary drug discovery platform of the latter to identify novel agents that induce degradation of specified drug targets.
Merck's Keytruda Gets 2nd Label Expansion Approval in June
by Zacks Equity Research
Merck (MRK) receives FDA approval for Keytruda's label expansion in small cell lung cancer indication, marking the drug's first approval in this indication.
Sanofi Partners Google to Build Healthcare Innovation Lab
by Zacks Equity Research
Sanofi (SNY) signs a partnership pact with Google to develop a new virtual healthcare innovation lab for modernizing future medicines and healthcare services with sophisticated data technologies.
AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use
by Zacks Equity Research
AstraZeneca (AZN) and Merck's PARP inhibitor, Lynparza, gets approval in EU as a front-line therapy for BRCA-mutated advanced ovarian cancer.
Glaxo Inks Genome Research Deal With University of California
by Zacks Equity Research
Glaxo (GSK) signs a five-year collaboration contract with the University of California to build a new laboratory for developing new medicines with the aid of CRISPR technologies.
Glaxo's Nucala Gets CHMP Nod for 2 Self-Administered Options
by Zacks Equity Research
GlaxoSmithKline (GSK) announces that the EMA???s Committee for Medicinal Products for Human Use has issued a positive opinion for two self-administered options of its asthma drug, Nucala.
Emergent (EBS) Wins HHS Contract to Supply VIGIV Product
by Zacks Equity Research
Shares of Emergent (EBS) rise after the company gets a 10-year HHS contract valued at roughly $535 million to dispense VIGIV product to the U.S. government for supporting its smallpox awareness drive.
Gilead Gains 6.8% YTD as HIV Franchise Maintains Momentum
by Zacks Equity Research
Gilead (GILD) up 6.9% in the year so far on strong performance of HIV franchise and pipeline development efforts.
Glaxo's Shingles Vaccine Shingrix Gets Approval in China
by Zacks Equity Research
GlaxoSmithKline (GSK) plans to launch Shingrix in China in several phases starting 2020.
Pharma Stock Roundup: MRK's Cancer Biotech Buyout, ABBV, LLY's Pipeline Updates
by Kinjel Shah
Key highlights of the week include Merck's (MRK) offer to buy private cancer biotech and AbbVie (ABBV) and Lilly's (LLY) updates from clinical studies.
Merck's Keytruda Fails in Late-Stage Breast Cancer Study
by Zacks Equity Research
Merck's (MRK) Keytruda fails in a late-stage study evaluating it as second- or third-line treatment for breast cancer.
Thermo Fisher Acquires GlaxoSmithKline's Drug Production Site
by Zacks Equity Research
The latest acquisition aligns with Thermo Fisher's (TMO) strategy of enhancing capabilities of its Pharma Services through the right balance of capital investment, and merger and acquisition.
Theravance (TBPH) Q1 Loss Widens, Revenues Miss Estimates
by Zacks Equity Research
Theravance Biopharma (TBPH) retains its earlier issued guidance for 2019 operating loss sans non-cash share-based compensation in the range of $210-$230 million.
Clovis (CLVS) Q1 Earnings Top Estimates, Rubraca Sales Strong
by Zacks Equity Research
Clovis (CLVS) reports encouraging first-quarter 2019 results. Rubraca maintains market share during the quarter.
What's in Store for Axsome (AXSM) This Earnings Season?
by Zacks Equity Research
On Axsome's (AXSM) first-quarter earnings call, investors will look for its progress with the CNS pipeline candidates and the regulatory updates on the same.
The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo
Emergent (EBS) Earnings & Revenues Miss Estimates in Q1
by Zacks Equity Research
Emergent (EBS) incurs loss in the first quarter and misses on revenues as well.
Gilead (GILD) Earnings Beat, Revenues Miss Estimates in Q1
by Zacks Equity Research
Biotech bigwig Gilead's (GILD) Q1 financial report is mixed with dismal sales and an earnings beat.
Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV Drugs Get EU Nod
by Kinjel Shah
Merck (MRK), Pfizer (PFE), Lilly (LLY) announce Q1 results. European Commission grants approval to AbbVie's (ABBV) Skyrizi and Sanofi's (SNY) Zynquista.
Glaxo (GSK) Beats on Q1 Earnings & Sales, Shingrix Impresses
by Zacks Equity Research
Glaxo (GSK) beats earnings and sales estimates for the first quarter. Strong sales growth of vaccine portfolio boosts sales. However, Advair generic severely impacts the drug's U.S. sales.
Can Allergan (AGN) Beat Earnings Estimates Again in Q1?
by Zacks Equity Research
Allergan's (AGN) key products like Botox are likely to provide top-line support in Q1 as loss of exclusivity of several products hurts sales
Glaxo (GSK) Beats Earnings & Revenue Estimates in Q1
by Zacks Equity Research
Glaxo beats both earnings and sales estimates in the first quarter of 2019.